The effects of the protein kinase C (PKC) activator and downregulator bryostatin 1 were examined with respect to paclitaxelinduced apoptosis and antiproliferative activity in human myeloid leukemia cells (U937) displaying enforced expression of the anti-apoptotic protein Bcl-x L . Overexpression of Bcl-x L blocked various aspects of paclitaxel-mediated apoptosis, including caspase-3 activation, degradation of poly(ADPribose) polymerase (PARP), loss of mitochondrial membrane potential (⌬ ⌿ m ), and release of cytochrome c. However, subsequent (but not prior) exposure of paclitaxel-treated U937/Bclx L cells (500 nM; 6 h) to bryostatin 1 (10 nM; 15 h) restored the extent of apoptosis, caspase activation, and mitochondrial damage to levels approximating those in paclitaxel-treated empty-vector control cells (U937/Neo). Potentiation of paclitaxel-induced apoptosis by bryostatin 1 in U937/Bcl-x L cells occurred primarily in the G 2 M cell population, and was associated with alterations in Bcl-x L gel mobility and a reduction in paclitaxel-mediated stimulation of CDK1 activity. Enhancement of paclitaxel-induced apoptosis by bryostatin 1 in Bcl-x L overexpressors was accompanied by a corresponding reduction in clonogenic potential. In contrast to its effects on apoptosis, bryostatin 1 failed to restore paclitaxel-mediated increases in free Bax levels in U937/Bcl-x L cells. Lastly, the actions of bryostatin 1 were mimicked by a pharmacologic inhibitor of the MEK1/MAP kinase pathway (PD98059), but not by SB203580, an inhibitor of p 38 MAP kinase. Moreover, sequential exposure of both U937/Neo or/Bcl-x L cells to paclitaxel followed by bryostatin 1 or PD98059 was associated with a net reduction in MAP kinase activity. Collectively, these findings indicate that protection against paclitaxel-mediated mitochondrial dysfunction and apoptosis in human U937 leukemia cells conferred by Bcl-x L overexpression can be substantially overcome by bryostatin 1 and possibly other agents that interrupt the MAP kinase signal transduction pathway.
Introduction
Paclitaxel (Taxol) represents a member of the taxane family, and has established activity against a variety of malignant disorders including leukemia. 1 In contrast to Vinca alkaloids such as vincristine, which disrupt microtubule assembly and function, paclitaxel acts by stabilizing tubulin dimers, thereby interfering with microtubular disassembly and ultimately inducing apoptosis. 2 Treatment of cells with paclitaxel results in G 2 M arrest 3 and activation of the cyclin-dependent kinase (CDK) CDK1 (p 34 cdc2 ), 4 although the specific contributions of these actions to lethality remain to be fully elucidated.
Bcl-2 and its relatives represent homologs of the C. elegans death gene family of pro-and anti-apoptotic proteins. 5 Bcl-2 heterodimerizes with and opposes the actions of the pro- apoptotic Bax protein; moreover, the ratio of Bcl-2/Bax can determine whether a cell lives or dies following toxic insult. 6 Bcl-x is expressed, through an alternative splicing mechanism, as a long form, Bcl-x L , which acts like Bcl-2, and a short form, Bcl-x S , which promotes cell death. 7 The mechanism by which Bcl-2 and Bcl-x L oppose apoptosis is uncertain, but the results of several studies suggest that these proteins block early mitochondrial events associated with the cell death program, including induction of the mitochondrial permeability transition (PT), loss of mitochondrial membrane potential (⌬ ⌿ m ), and release of cytochrome c into the cytosol. 8, 9 Cytochrome c has recently been shown to function as part of a complex consisting of apotosis-activating factor-1 (Apaf-1), the mammalian homolog of Ced-4, dATP, and Apaf-3 (caspase 9), which cleaves and activates the Yama protease (caspase-3; CPP-32), leading to proteolysis of multiple downstream cellular targets. 10 Recent studies have shown that overexpression of Bcl-x L in human leukemia cells blocks taxol-mediated apoptosis as well as accompanying mitochondrial perturbations (eg cytochrome c release). 11, 12 The macrocyclic lactone bryostatin 1 is a non-tumorpromoting activator of the serine/threonine kinase, protein kinase C (PKC), and is currently undergoing phase I/II evaluation in humans. 13 In human leukemia cells, bryostatin 1 promotes apoptosis induced by the antimetabolite 1-␤-d-arabinofuranosylcytosine (ara-C) in a sequence-dependent manner. 14 Moreover, bryostatin 1 has been found capable of reversing, at least in part, blockade of ara-C-mediated activation of the caspase cascade in HL-60 human leukemic cells displaying enforced expression of Bcl-2. 15 The present investigation was prompted by several considerations. First, given evidence that Bcl-2 and Bcl-x L may exert disparate cytoprotective profiles, 16 it would be important to determine whether the ability of bryostatin 1 to overcome distal blockade of the cell death program could be extended to the latter anti-apoptotic family member. Secondly, we have recently reported that subsequent, but not prior exposure of paclitaxel-treated leukemic cells (U937) to bryostatin 1 leads to a significant increase in apoptosis and synergistic antileukemic effects for the combination. 17 Lastly, ectopic expression of Bcl-x L has recently been shown to protect U937 cells from paclitaxel-mediated lethality. 12 Consequently, a second goal of this study was to determine whether bryostatin 1 could overcome Bcl-x L -mediated protection against paclitaxel-induced cell death, and if so, what factors might be involved in this phenomenon.
Materials and methods

Cells
The human monocytic leukemic cell line U937, isolated from the peripheral blood of a patient with diffuse histiocytic lymphoma, was maintained as previously described. 17 Cells were cultured in RPMI 1640 medium supplemented with sodium pyruvate, MEM essential vitamins, l-glutamate, penicillin and streptomycin, and 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT, USA). They were maintained in a 37°C, 5% CO 2 , fully humidified incubator, passed twice weekly, and prepared for experimental procedures when in log phase growth (cell density р4 × 10 5 cells/ml). To obtain Bcl-x L overexpressors, the cDNA for Bcl-x L (provided by Dr Craig Thompson, University of Chicago, Chicago, IL, USA) was cloned into an expression vector (pcDNA 3.1; Invitrogen, Carlsbad, CA, USA) containing a G418 resistance marker. U937 cells were transfected by electroporation in a 0.4 cm cuvette using a BTX 600 electromanipulator (BTX, San Diego, CA, USA) set at 264 V, 750 F, and 480 W). After 3 days incubation in fresh medium, the resistant cell population was cultured under selection pressure in medium containing 400 g/ml G418. Parallel transfections were carried out utilizing an empty vector. Single cell populations were obtained by limiting dilution, and expanded first in 12-well plates and subsequently in 25 cm 2 flasks. The progeny of invidual clones was subjected to Western blot analysis (see below), and lines expressing the highest levels of Bcl-x L protein (eg U937/Bcl-x L ), as well as the empty vector (U937/Neo) selected for the experiments described below. In most studies, responses of a second Bcl-x L -overexpressing line (U937/Bcl-x L /A1) were assessed, and in all cases found to be identical to those of U937/Bcl-x L cells.
Drugs and chemicals
Paclitaxel was purchased from Sigma (St Louis, MO, USA), stored in light-protected containers at −20°C, and dissolved in sterile dimethylsulfoxide (DMSO; Sigma) before use. Bryostatin 1 was provided by the Cancer Treatment and Evaluation Program, NIH, Bethesda, MD, USA and stored desiccated at −20°C. It was formulated in sterile DMSO, and subsequently diluted in RPMI medium so that the final concentration of DMSO was in all cases р0.05%. PD98059 and SB203580 were purchased from Calbiochem, San Diego, CA, USA, dissolved in sterile DMSO, and diluted in RPMI medium as above. Alkaline phosphatase was purchased from Boehringer Mannheim, Indianapolis, IN, USA, stored at 4°C, and reconstituted in buffer supplied by the manufacturer prior to use.
Assessment of apoptosis
Following drug exposures, cytocentrifuge preparations were stained with Wright-Giemsa and viewed by light microscopy to evaluate features of cellular differentiation as well as apoptosis (ie cell shrinkage, nuclear condensation, formation of apoptotic bodies etc) as previously described. 17 For the latter studies, the percentage of apoptotic cells was determined by evaluating у500 cells/condition in triplicate. We have previously reported that the incidence of apoptosis as determined by these morphological criteria correlates very closely with the degree of low molecular weight DNA fragmentation assayed quantitatively by spectrofluorometry, and qualitatively with the amount of internucleosomal DNA fragmentation determined by agarose gel electrophoresis. 18 
Agarose gel electrophoresis
For qualitative assessment of internucleosomal DNA fragmentation, DNA was extracted from cell lysates following appropriate drug treatment and subjected to agarose gel electrophoresis using a technique previously described in detail. 18 
Western analysis
A minor modification of a previously described method was employed. 15 
Phosphatase treatment
Following treatment with taxol followed by bryostatin 1, cells were lysed with 1% Triton X-100 lysis buffer (25 mm Tris base, 0.1% ␤-mercaptoethanol, 1% Triton X-100) and centrifuged at 12 000 g for 10 min at 4°C. The supernatants were then incubated in lysis buffer for 4 h at 37°C in the presence or absence of alkaline phosphatase (1 unit/25 g protein). SDS-PAGE immunoblot analysis was then performed utilizing antiBcl-2 monoclonal antibody and enhanced chemiluminescence as described above.
Cell cycle analysis
After treatment, cells were pelleted at 500 g and resuspended in 70% ethanol. The cell pellets were incubated on ice for 1 h, and resuspended in 1 ml cell cycle buffer (0.38 mm sodium citrate, 0.5 mg/ml RNase A, and 0.01 mg/ml propidium iodide (all Sigma) at a concentration of 10 6 cells/ml. Samples were stored in the dark before analysis at 4°C (usually within 24 h), and analyzed on a Becton Dickinson FACScan flow cytometer (Cambridge, MA, USA) utilizing a commercially available software program (ModFit LT 2.0; Verity Software, Topsham, ME, USA).
Assessment of mitochondrial function Determination of mitochrondrial membrane potential (⌬⌿ m ):
Mitochrondrial membrane potential was monitored utilizing 3,3-dihexyloxacarbocyanine iodide (DiOC6). For each condition, 4×10 5 cells were incubated for 15 min at 37°C in 1 ml of 40 nm DiOC6 19 and subsequently analyzed using a Becton Dickinson FACScan cytofluorometer with excitation and emission settings of 488 and 525 nm, respectively. Control experiments documenting the loss of ⌬⌿ m were performed by exposing cells to 5 m carbamoyl cyanide m-chlorophenylhydrazone(mCCCP) (15 min, 37°C), an uncoupling agent that abolishes the mitochondrial membrane potential.
Preparation of S-100 fractions and assessment of cytochrome c release
U937 cells overexpressing Bcl-x L and empty vector-containing controls were harvested after drug treatment by centrifugation at 600 g for 10 min at 4°C. The cytosolic S-100 fraction was prepared as described, 15 with minor modifications. Cells pellets were washed once with ice-cold phosphate-buffered saline (PBS) and resuspended in five volumes of buffer A (20 mm Hepes-KOH, pH 7.5, 10 mm KCl, 1.5 mm MgCl 2 , 1 mm sodium EDTA, 1 mm sodium EGTA, 1 mm dithiothreotol, and 0.1 mm phenylmethyl sulfonyl fluoride, 250 mm sucrose). After chilling for 30 min on ice, the cells were disrupted by 15 strokes of a glass homogenizer. The homogenate was centrifuged twice to remove unbroken cells and nuclei (750 g, 10 min, 4°C). S-100 fractions (supernatants) were then obtained by centrifugation at 100 000 g, 60 min at 4°C. All steps were performed on ice or 4°C. Cytochrome c release into the S-100 fraction for each condition was assessed by Western blot analysis of the resulting fractions as detailed above.
CDKl activity
Following treatment, cells were washed and lysed in 1% NP-40 lysis buffer (50 mm Tris, 150 mm NaCl, 2 mm EDTA, 2 mm EGTA, 1 mm PMSF (phenylmethylsufonyl fluroide), 1 mm dithiothreitol, 10 g/ml leupeptin, 10 g/ml aprotinin, and 1% NP-40 (all Sigma)). Lysates were then centrifuged at 15 000 g for 15 min at 4°C. For each condition, 300 g of supernatant protein was incubated with 1 g of anti-CDK1 antibody (Santa Cruz Biotechnology) and immunoprecipitated with Dynabeads bound to goat anti-mouse IgG (Dynal). After washing the beads five times with lysis buffer, immune complexes were resuspended in 10 l of kinase buffer (50 mm Tris, 10 mm MgCl 2 and 1 mm dithiothreitol. Kinase activity was assayed in a 25 l volume by mixing 5 l of sample extract, 10 l of 2.5 × c kinase buffer (with or without 0.5 mg/ml histone H1), and 10 l of 0.3 mCi of ␥-32 P/ml (6000 Ci/mmol; NEN Dupont, Wilmington, DE, USA) in 50 mm ATP). After 15 min at 32°C, reactions were teminated by spotting 20 l of the reaction mixture on to phosphocellulose disks and washing three times with 0.8% H 3 PO 4 . The amount of labeled phosphate incorporation into histone H1 was determined by scintillation counting.
MAP kinase activity
Briefly, after exposure of U937/Neo and U937/Bcl-x L cells to paclitaxel followed by bryostatin 1 or PD98059, immunoprecipitates were obtained from cell homogenates as described in detail previously. 20 Fifty l aliquots were then incubated with an equal volume of buffer containing 0.2 mm ␥- 
Cloning studies
A previously described method was employed. 15 Briefly, following drug treatment, cells were washed three times in drugfree RPMI medium containing 5% FCS and cell counts determined using a Model ZBI Coulter counter (Hialeah, FL, USA). After normalization, cells were plated in 18 mm 12-well plates (Costar, Cambridge, MA, USA). Each well contained 1 ml of supplemented RPMI 1640 medium, 20% FCS, 0.3% Bacto agar (Difco, Detroit, MI, USA) and 4×10 the cell number at the end of the initial incubation period by the cloning efficiency. Values for each condition were expressed as a percentage relative to untreated controls.
Statistical analysis
The significance of differences between experimental conditions was determined utilizing the two-tailed Student's t-test.
Results
Western blot analysis was employed to characterize Bcl-x L protein expression in transfected cell lines (Figure 1a ). Both (a) Expression of Bcl-2 family members in transfectant cells. U937 cells were transfected with plasmids containing either an empty vector (U937/Neo) or cDNA encoding Bcl-x L (U937/Bcl-x L ), after which clones were selected in G418 as described in the text. Cell lysates from these as well as untransfected parental U937 cells (25 g protein/lane) were subjected to Western blot analysis using antibodies directed against Bcl-x L , Bcl-2 and Bax. An additional study yielded equivalent results. (b) Effect of bryostatin 1 on paclitaxelinduced apoptosis. Logarithmically growing U937/Neo and U937/BcI-x L cells were exposed to 500 nm paclitaxel for 6 h, washed free of drug, and incubated for an additional 15 h in the presence or absence of 10 nm bryostatin 1. Cytospin preparations were obtained, stained with Wright-Giemsa, and the percentage of apoptotic cells determined by morphological assessment of у500 cells/condition using criteria described in Materials and methods. Results represent the means ± s.d. for three separate experiments performed in triplicate.*, Significantly lower than values obtained for U937/Neo cells; P р0.01; **, not significantly different from values obtained for U937/Neo cells exposed to paclitaxel alone; P у0.05. untransfected U937 cells (U937/wt) and empty-vector controls (U937/Neo) expressed barely discernible levels of Bcl-x L protein. Transfection of cells with the Bcl-x L expression construct resulted in a very significant increase in Bcl-x L protein levels. In contrast, levels of Bcl-2 and Bax were equivalent in the three cell lines.
The effects of subsequent exposure to bryostatin 1 (10 nm; 15 h) on paclitaxel-induced apoptosis (500 nm; 6 h) in U937/Neo and U937/Bcl-x L cells are shown in Figure 1b . As previously reported, 11 overexpression of Bcl-x L conferred significant protection against paclitaxel-mediated cell death (eg 12.6 ± 2.2% vs 33.9 ± 3.7%; P р 0.001); moreover, subsequent exposure of paclitaxel-treated U937/Neo cells to a minimally toxic concentration of bryostatin 1 increased the extent of apoptosis by approximately 85%. Significantly, bryostatin 1 also increased paclitaxel-mediated apoptosis in resistant Bcl-x L overexpressing cells. While the extent of apoptosis after exposure to both agents continued to be greater in U937/Neo controls than in U937/Bcl-x L cells (57.9 ± 5.6 vs 40.4 ± 4.9%; P Ͻ 0.05), the degree of apoptosis in the latter line following sequential drug treatment was at least as great as that observed in empty-vector controls treated with paclitaxel alone (40.4 ± 4.9 vs 33.9 ± 3.7%; P Ͼ 0.05). Similar results were obtained with a second Bcl-x L -overexpressing cell line (Bcl-x L /A1; data not shown). Thus, subsequent exposure to a minimally toxic concentration of bryostatin 1 effectively circumvented Bcl-x L -mediated protection against paclitaxelinduced cell death. In separate studies, prior exposure of either U937/Neo or Bcl-x L -overexpressing cells to bryostatin 1 (10 nm) for 15 h did not lead to a significant increase in paclitaxel-mediated apoptosis (data not shown).
The results of clonogenic survival studies are shown in Figure 2. A 15-h exposure to bryostatin 1 (10 nm) alone reduced colony formation by approximately 54% in U937/neo cells but by only approximately 15% in U937/Bcl-x L cells. When cells containing empty vector were plated in soft agar 15 h after a 6-h exposure to 500 nm paclitaxel, colony formation was reduced to 0.9 ± 0.5% of controls, vs 6.1 ± 1.5% for
Figure 2
Effect of bryostatin 1 on paclitaxel-mediated inhibition of clonogenicity. Following sequential exposure of U937/Neo and U937/Bcl-x L cells to paclitaxel followed by bryostatin 1, cells were washed free of drug, resuspended in fresh medium, and plated in soft agar as described in the text. Colonies, consisting of groups of у50 cells, were scored on day 12. Values, expressed as a percentage of control cell colony formation, represent the means for three separate experiments performed in triplicate ± s.d.*, Not significantly different from values obtained for U937/Neo cells exposed to paclitaxel alone; P у 0.05. U937/Bcl-x L cells (P р 0.005). Sequential exposure of cells to paclitaxel followed by bryostatin 1 reduced colony formation to 0.14 ± 0.12% of control values in U937/neo cells, compared to 1.1 ± 0.5% for U937/Bcl-x L cells. Notably, survival of U937/Bcl-x L treated with paclitaxel and bryostatin 1 did not differ significantly from that of empty-vector controls treated with paclitaxel alone (P у 0.05). Consequently, a marginally inhibitory concentration of bryostatin 1 was able to restore the growth-suppressive effects of paclitaxel in Bcl-x L -overexpressing cells to those observed in wild-type controls.
Cell cycle perturbations in cells exposed to paclitaxel ± bryostatin 1 were then examined (Figure 3) . In both U937/Neo and U937/Bcl-x L cells, paclitaxel treatment resulted in an accumulation of cells in G 2 M, although this effect was slightly greater in the Bcl-x L -overexpressing line (55.2 ± 5.2 vs 44.8 ± 2.8%; P р 0.05). In both cell types, sequential exposure to paclitaxel followed by bryostatin 1 led to a significant increase in the sub-G 1 population, corresponding to apoptotic cells containing hypodiploid quantities of DNA. Furthermore, the increase in the hypodiploid population was accompanied by reciprocal reductions in the percentage of cells in the G 2 M fraction (eg 16.3 ± 4.3% and 21.3 ± 3.8% for U937/Neo and/Bcl-x L cells, respectively). These findings suggest that subsequent exposure of paclitaxel-treated cells to bryostatin 1 promotes apoptosis in the G 2 M population, particularly in the case of cells overexpressing Bcl-x L .
To assess the effects of bryostatin 1 on the ability of paclit-
Figure 3
Cell cycle analysis of cells exposed to paclitaxel ± bryostatin 1. (a) U937/Neo and (b) U937/Bcl-x L cells were sequentially exposed to paclitaxel followed by bryostatin 1 as described above, after which they were fixed, stained with propidium iodide, and cell cycle analysis performed as described in the text. The percentages of cells in the sub-G 1 (apoptotic), G 0 /G 1 S and G 2 M populations after each treatment are shown, and represent the means for three separate experiments ± s.d.
axel to activate the apoptotic protease cascade in Bcl-x L -overexpressing cells, Western blot analysis was employed ( Figure  4) . Cleavage (and activation) of the 32 kDa procaspase 3 species in U937/Neo cells was minimal following bryostatin 1 treatment, more extensive after incubation with paclitaxel, and virtually complete after sequential exposure (Figure 4a) . In Bcl-x L -overexpressing cells, neither bryostatin 1 nor paclitaxel alone led to a discernible reduction in expression of procaspase-3. However, sequential exposure of these cells to paclitaxel followed by bryostatin 1 clearly reduced procaspase 3 levels, although not to the extent as that seen in U937/Neo cells. Parallel results were observed when poly (ADP-ribose) polymerase (PARP) cleavage was monitored (Figure 4b) . Thus, exposure of U937/Neo cells to paclitaxel led to degradation of 116 kDa PARP to its 85 kDa cleavage product, and this process was enhanced by subsequent treatment with bryostatin 1. In U937/Bcl-x L cells, paclitaxel-mediated PARP degradation was largely blocked. However, when paclitaxel-treated Bcl-x L overexpressors were subsequently exposed to bryostatin 1 (at a concentration which by itself exerted no effect), PARP cleavage was substantially enhanced. These results indicate that subsequent exposure to bryostatin 1 overcomes, at least in part, the ability of Bcl-x L to block paclitaxel-mediated activation of the apoptotic caspase cascade.
Western analysis of Bcl-x L and Bax proteins was then performed on lysates obtained from cells exposed to paclitaxel ± bryostatin 1 ( Figure 5 ). As previously shown in Figure 1 , U937/Neo cells expressed barely discernible levels of Bcl-x L , and no changes could be seen following drug exposure (data not shown). Because the very high levels of Bcl-x L expression in the mutant line made interpretation of drug effects on protein mobility difficult, the amount of protein loaded on to gels (10 g), the dilution of primary antibody (1:2000) and the autoradiograph exposure interval (20 s) were substantially reduced (Figure 5a ). In untreated U937/Bcl-x L cells, Bcl-x L migrated as a doublet (Figure 5a ; upper panel). When cells were exposed to bryostatin 1, a diffuse broadening and increase in intensity of the protein bands was observed, a phenomenon similar to that which we have previously described in Bcl-2-overexpressing HL-60 cells treated with bryostatin 1 or PKC inhibitors. 15 Incubation of cells with paclitaxel also resulted in a broadening of the protein bands, although this effect was less marked than in the case of bryostatin 1. Furthermore, sequential exposure of U937/Bcl-x L to
Figure 4
Activation of the caspase cascade by paclitaxel ± bryostatin 1. U937/Neo and U937/Bcl-x L cells were exposed to paclitaxel ± bryostatin 1 as described above, after which cell lysates were obtained and subjected to Western blot analysis as outlined in Effects of paclitaxel ± bryostatin 1 on Bcl-x L mobility and Bax expression. (a) U937/Cells were exposed to paclitaxel ± bryostatin 1, and lystates subjected to Western blot analysis as described in Materials and methods. Because of the high levels of Bcl-x L expression in the transfectant cell line, reductions in protein loading (10 g), paclitaxel followed by bryostatin 1 resulted in a further potentiation of this phenomenon. As described in our previous study, 15 treatment of lysates with alkaline phosphatase prior to Western blot analysis substantially antagonized broadening of the protein bands (Figure 5a, third panel) . This finding is consistent with the notion that at least some of the changes in appearance of the Bcl-x L protein observed in cells exposed to bryostatin 1 ± paclitaxel reflect alterations in mobility resulting from Bcl-x L phosphorylation.
Treatment of either U937/Neo or U937/Bcl-x L cells with paclitaxel, bryostatin 1, or the sequence paclitaxel followed by bryostatin 1 had no discernible effect on total Bax expression (Figure 5b) . However, when U937/Neo cells were exposed to paclitaxel and free Bax expression was monitored in cell lysates immunodepleted of Bax/Bcl-2 and Bax/Bcl-x L heterodimers, a clear increase in free Bax levels was noted (Figure 6b, lower panel) . Moreover, subsequent exposure of these cells to bryostatin 1 resulted in a further increase in free Bax expression. As previously reported, 11 overexpression of Bcl-x L essentially abrogated paclitaxel-mediated augmentation of free Bax levels. However, subsequent treatment of U937Bcl-x L cells with bryostatin 1 failed to prevent Bcl-x L from blocking increases in free Bax expression accompanying paclitaxel exposure. Together, these results indicate that the capacity of bryostatin 1 to enhance paclitaxel-induced apoptosis in Bcl-x L -overexpressing cells proceeds through a mechanism independent of free Bax induction.
Bcl-x L overexpression has been shown to block paclitaxel- mediated mitochondrial perturbations associated with apoptosis. 11 To assess the effects of bryostatin 1 on this process, mitochondrial membrane potential (⌬⌿ m ) was monitored using the lipophilic fluorochome DiOC 6 (Figure 6a ). Following exposure to paclitaxel, the reduction in ⌬⌿ m (reflected by an increase in the percentage of cells exhibiting 'low' levels of DiOC 6 accumulation) was attenuated in Bcl-x L -overexpressing cells (ie 29.3 ± 7.2% vs 53.8 ± 6.8% for U937/Neo cells; P р 0.05). However, when U937/Bcl-x L cells were exposed to the sequence paclitaxel followed by bryostatin 1, the reduction in ⌬⌿ m was equivalent to that observed in U937/Neo cells treated with paclitaxel alone (51.4 ± 4.8% vs 53.8 ± 6.8%; P у 0.05). Parallel results were obtained when release of cytochrome c into the cytosolic S-100 fraction was examined (Figure 6b ). Thus, in U937/Neo cells, paclitaxelstimulated release of cytochrome c release was enhanced by subsequent exposure to bryostatin 1. As previously described, 11 Bcl-x L overexpression attenuated cytochrome c release following paclitaxel exposure. Significantly, sequential exposure of U937/Bcl-x L cells to paclitaxel and bryostatin 1 increased the extent of cytochrome c release to levels that were at least as great as those observed in U937/Neo cells treated with paclitaxel alone. These findings suggest that bryostatin 1 antagonizes the capacity of Bcl-x L to block paclitaxel-mediated perturbations in leukemic cell mitochondrial integrity.
Exposure of cells to paclitaxel leads to an increase in activity of CDK1 (p 34 cdc2 ). 4 Attempts were therefore made to determine what effect bryostatin 1 might have on this event (Figure 7 ). While treatment with bryostatin 1 alone was ineffective, exposure to paclitaxel resulted in more than a 200%
Figure 7
Effect of paclitaxel and bryostatin 1 on CDK1 activity. (a) Logarithmically growing U937/Neo and U937/Bcl-x L cells were exposed to paclitaxel (500 nm; 6 h), washed, and incubated in either drug-free medium or medium containing 10 nm bryostatin 1 for an additional 15 h. At the end of the incubation period, CDK1 activity in immunoprecipitates was determined as described in the text, and expressed as a percentage of untreated control values. (b) Alternatively, cytospin preparations were obtained, stained with WrightGiemsa, and the percentage of mitotic cells determined under light microscopy by scoring у500 cells/condition. In each case values represent the means for three separate experiments performed in triplicate ± s.d.*, Significantly less than values obtained for cells exposed to paclitaxel alone; P р 0.01; **, P р 0.05. increase in CDK1 activity in both U937/Neo and U937/Bclx L cells (Figure 7a) . However, the paclitaxel-mediated increase in CDK1 activity was attenuated in cells subsequently exposed to bryostatin 1 in both cell lines. Interestingly, the response pattern of CDK1 activity following drug treatment closely paralleled changes in the mitotic index (Figure 7b ). Together, these findings raise the possibility that paclitaxel-mediated increases in CDK1 activity correspond to the extent of G 2 M arrest, and that subsequent exposure to bryostatin 1 attenuates such increases by depleting (through potentiation of apoptosis) the mitotic cell fraction.
Finally, we have previously reported that potentiation of paclitaxel-mediated apoptosis by bryostatin 1 in parental U937 cells can be mimicked by the MAP kinase kinase (MEK1) inhibitor, PD98059. 17 Attempts were therefore made to determine whether this agent could also overcome the inhibitory effects of Bcl-x L on paclitaxel-induced cell death (Figure 8a) . Consistent with the previous report, 17 PD98059 increased the extent of paclitaxel-mediated apoptosis in U937/Neo cells, although SB203580, a specific inhibitor of p 38MAP kinase, 21 did not. Moreover, subsequent exposure of paclitaxel-treated U937/Bcl-x L cells to PD98059 (10 m) Figure 8 (a) Modulation of paclitaxel-mediated apoptosis by inhibitors of p 42/44 and p 38 MAP kinase. Logarithmically growing empty-vector (Neo) or U937/Bcl-x L cells (x L ) were incubated in either drug-free medium or medium containing 500 nm paclitaxel (Tax) for 6 h, after which they were washed and resuspended in medium containing 20 m PD98059 or SB203580 for an additional 15 h. At the end of this period, cytospin preparations were obtained, stained with Wright-Giemsa, and the percentage of apoptotic cells determined by scoring у500 cells/condition. Values represent the means for three separate experiments performed in triplicate ± s.d.*, Equivalent to values obtained for paclitaxel-treated U937/Neo cells; P у 0.05.**, Not significantly greater than values obtained for paclitaxel-treated U937/Bcl-x L cells; P у 0.05. (b) Effect of paclitaxel ± bryostatin 1 or PD98059 on MAP kinase activity in U937/Neo and U937/Bcl-x L cells. Cells were exposed to 500 nm paclitaxel (Tax) for 6 h, washed, and incubated in drug-free medium or medium containing 10 nm bryostatin 1 (bry) or 10 m PD98059 (PD) for an additional 15 h, after which MAP kinase activity was assayed as outlined in the text. Values are expressed as percentages relative to untreated control cells, and represent the means for three separate experiments ± s.d. Control values, expressed as c.p.m. 32 P incorporated into myelin basic protein, for U937/Neo and U937/Bcl-x L cells were 1.27 ± 0.22 and 1.04 ± 0.23, respectively (P у 0.05).*, Significantly less than values obtained for untreated control cells; P р 0.05. restored apoptosis to levels that did not differ significantly from those seen in U937/Neo cells treated with paclitaxel alone (26.2 ± 2.4 vs 29.3 ± 3.8%; P у 0.05). In contrast, SB203580 did not lead to a significant increase in the extent of paclitaxel-induced apoptosis in Bcl-x L cells (15.4 ± 2.4 vs 13.0 ± 2.3%; P у 0.05). Lastly, whereas exposure of U937/Neo or U937/Bcl-x L cells to paclitaxel, bryostatin 1, or PD98059 alone did not modify basal MAP kinase activity, sequential treatment of both cell lines with paclitaxel followed by bryostatin 1 or PD98059 was associated with modest but statistically significant reductions in MAP kinase activity (eg, 29-36%; P р 0.05 in each case; Figure 8b ). Collectively, these findings suggest that interruption of the p 42-44MAP kinase, but not the p 38MAP kinase pathway, may be involved in promoting paclitaxel-induced apoptosis in Bcl-x L -overexpressing cells.
Discussion
The present results demonstrate that blockade of paclitaxelmediated apoptosis in U937 cells by the anti-apoptotic protein Bcl-x L can be substantially reversed by subsequent exposure to the PKC activator (and down-regulator) bryostatin 1. Previous studies have shown that pretreatment of HL-60 cells overexpressing Bcl-2 with bryostatin 1 partially restores the ability of ara-C to activate the apoptotic protease cascade. 15 Moreover, exposure of U937 leukemia cells to bryostatin 1 after, but not before, either ara-C or paclitaxel results in potentiation of apoptosis. 14, 17 These observations suggest that the sequence-dependent factors that permit bryostatin 1 to potentiate drug-induced apoptosis in leukemic cells may be similar to those responsible for overcoming Bcl-2-or Bclx L mediated cytoprotective actions. Inasmuch as Bcl-2 and Bcl-x L exert differential protective effects toward various chemotherapeutic agents, 16 such findings support the notion that bryostatin 1 acts at a common regulatory step in the apoptotic pathway.
The mechanism(s) by which Bcl-2 and Bcl-x L inhibit apoptosis is (are) not known with certainty but may involve attenuation of mitochondrial damage, eg by antagonism of ⌬⌿ m collapse, 19 cytochrome c release, 9 or by promotion of H + efflux. 22 Furthermore, prevention of drug-induced apoptosis by Bcl-2 or Bcl-x L is accompanied by a corresponding diminution in the loss of mitochondrial transmembrane potential. 23 Therefore, bryostatin 1 may oppose Bcl-x L cytoprotective actions by lowering the threshold for paclitaxelmediated mitochondrial dysfunction. In this context, the differentiation-inducing agent sodium butyrate promotes mitochondrial cytochrome c release, 24 and bryostatin 1, a weak inducer of U937 cell maturation 25 may act similarly. Recently, Bcl-x L has been shown to form a ternary complex with two components of the apoptosome, Apaf-1 and Apaf-3 (pro-caspase-9), 26 and may therefore act downstream of mitochondrial damage. In addition, Bcl-x L has been reported to act upstream of caspase activation in U937 cells exposed to various cytotoxic agents, including paclitaxel. 12 Consequently, it is possible that bryostatin 1 opposes Bcl-x L -related disruption of the Apaf-1/cytochrome c/Apaf-3 complex, 27 leading to activation of the proteolytic caspase cascade. It is important to note that bryostatin 1 substantially restored paclitaxel-mediated apoptosis without reversing the inhibitory influence of Bcl-x L on free Bax levels, a finding consistent with observations that the cytoprotective effects of Bcl-2 or Bcl-x L do not require direct interactions with Bax. 28 In light of evidence that Bax and the adenine nucleotide translocator (ANT) cooperate in triggering the mitochondrial permeability transition, 29 it is possible that antagonism of this process by Bcl-x L does not require heterodimerization with Bax. Efforts to test these hypotheses are underway.
Treatment of U937/Bcl-x L cells with bryostatin 1 ± paclitaxel led to marked alterations in appearance of the Bcl-x L protein, manifested by a diffuse broadening and increased intensity of the band on PAGE gels ( Figure 6 ). The effect of bryostatin 1 was similar to one which we have described in HL-60 cells ectopically expressing Bcl-2, 15 in which in vivo labeling with 32 P and 35 S, as well as elimination of alterations in Bcl-2 mobility by treatment of lysates with phosphatases implicated phosphorylation in the observed changes. It is unclear why drug exposure produces diffuse alterations in mobility of ectopically expressed Bcl-2, 15 or Bcl-x L (this study), in contrast to the more discrete, slow mobility bands that are seen following phosphorylation of endogenous protein. 30, 31 In this regard, it has recently been shown that both retinoic acid and paclitaxel induce serine phosphorylation of Bcl-2, but that these events exhibit qualitative differences. 32 It is possible that when Bcl-2 or Bcl-x L are driven by an ectopic promoter, induction of multiple phosphorylation states may contribute to the observed changes in the appearance of the protein.
The functional role of Bcl-2 phosphorylation in drugmediated lethality is uncertain. Microtubule-active agents such as paclitaxel induce Bcl-2 phosphorylation manifested by reduced protein mobility on PAGE gels, 33 an event recently extended to include Bcl-x L . 31 In prostate cancer cells, Bcl-2 phosphorylation by paclitaxel reduced heterodimerization with Bax. 30 Such findings suggest that phosphorylation of antiapoptotic members of the Bcl-2 family may be directly involved in paclitaxel-mediated lethality. However, it has recently been proposed that Bcl-2 phosphorylation by paclitaxel is related more to G 2 M arrest than induction of apoptosis. 34 Moreover, expression of a Bcl-2 construct containing a phosphorylation loop deletion rendered leukemic cells (HL-60) more rather than less sensitive to paclitaxelmediated apoptosis. 35 In this context, phosphorylation of Bcl-2 by bryostatin 1 in IL-3-dependent murine hematopoietic cells (FDC-P1/ER) decreased their susceptibility to growth factor deprivation-induced apoptosis, 36 and protected REH lymphocytic leukemia cells from drug-mediated apoptosis. 37 In contrast, phosphorylation of Bcl-2 by bryostatin 1 was associated with increased susceptibility of Bcl-2-overexpressing HL-60 cells to ara-C-induced cell death. 15 Collectively, these findings suggest that the functional consequences of bryostatin 1-related perturbations in Bcl-2 (and perhaps Bcl-x L ) phosphorylation may be both cell type-and stimulus-dependent.
Subsequent exposure of paclitaxel-treated cells to bryostatin 1 resulted in an increase in apoptotic cells accompanied by a reduction in the percentage of cells arrested in G 2 M in both Bcl-x L overexpressors as well as their empty-vector counterparts ( Figure 4 ). This suggests that Bcl-x L prevents cells unable to progress through mitosis from undergoing apoptosis, an action that is effectively antagonized by bryostatin 1. Exposure of cells to paclitaxel leads to an increase in p 34 cdc2 (CDK1) activity, 4 and it seemed plausible that bryostatin 1-mediated perturbations in CDKI might contribute to potentiation of cell death. While bryostatin 1 opposed paclitaxel-mediated increases in CDK1 activity in both Bcl-x L -overexpressing and empty-vector control cells, the results shown in Figures 4 and 8b suggest that this reflects depletion of the mitotic compartment accompanying enhanced apoptosis. It is noteworthy that PD98059, a MEK/MAPK inhibitor mimics the ability of bryostatin 1 to potentiate paclitaxel-mediated apoptosis in untransfected, 17 and Bcl-x L -overexpressing cells (this study). Furthermore, bryostatin 1-induced potentiation of ara-C-induced apoptosis in HL-60 cells has been linked to down-regulation of MAP kinase activity, 20 a finding consistent with both the present results (eg Figure 9a and b) , as well as reports that inhibition of MEK1/2 by PD98059 increases the susceptibility of cells to H 2 O 2 -mediated apoptosis. 38 Given evidence that the balance between the cytoprotective MAPK and the stressrelated protein kinase (SAPK) cascades may determine the fate of cells subjected to growth factor deprivation, 39 it is conceivable that interruption of the former pathway also promotes apoptosis in cells exposed to cytotoxic agents such as paclitaxel.
In a recent report by Lieu et al, 40 treatment of U937 cells with PD98059 prior to paclitaxel delayed progression of G 1 cells into the sensitive G 2 M compartment, thereby limiting apoptosis. PD98059 did not, however, significantly delay progression of S-phase cells, nor did it protect cells already in G 2 M from paclitaxel actions. It is important to note that PD98059 and paclitaxel concentrations of 80 m and 20 nm, respectively, were used in that study, vs 10 m and 500 nm employed here. In this context, it has recently been shown that the mechanism of cell death differs significantly in cells exposed to high vs low concentrations of paclitaxel. 41 Significantly, Lieu and coworkers administered PD98059 prior to paclitaxel, whereas PD98059 was given after paclitaxel in the present study. In this regard, MAP kinase has been shown by several groups to be actively involved in progression of cells through G 2 M and in the production of normal microtubules. 42, 43 Consequently, while prior inhibition of MAP kinase may partially prevent G 2 M entry and thereby limit paclitaxelmediated apoptosis, subsequent exposure of cells to MEK/MAP kinase inhibitors may promote lethality in cells already arrested in G 2 M following paclitaxel treatment. The mechanism by which such a phenomenon might occur is unclear, although the ability of MEK/MAP kinase inhibitors to disrupt the mitotic spindle checkpoint apparatus has recently been invoked. 44 In agreement with this notion, we have recently observed that subsequent exposure of leukemic cells to PD98059 increases apoptosis induced by ionizing radiation, which, like paclitaxel, also triggers G 2 M arrest. 45 In summary, the present findings indicate that bryostatin 1 potentiates paclitaxel-related lethality in leukemic cells ectopically expressing the anti-apoptotic protein Bcl-x L . Furthermore, this effect is associated with restoration of paclitaxel-induced mitochondrial dysfunction (loss of ⌬⌿ m and cytochrome c release) and caspase activation, events unaccompanied by increases in free Bax levels. Finally, the capacity of bryostatin 1 to potentiate paclitaxel-related apoptosis in Bcl-x L -overexpressing cells is sequence-dependent, and can be mimicked by an inhibitor of p 42-44 MAP kinase (but not p 38 MAP kinase). Such findings could have implications for attempts to enhance the antileukemic activity of agents such as paclitaxel through pharmacologic modulation of the PKC/MEK/MAPK signal transduction pathway. In this regard, plans to assess the activity of sequential administration of paclitaxel and bryostatin 1 in patients with hematologic malignancies are currently being developed.
